Cocrystal Pharma (COCP) Competitors

Cocrystal Pharma (NASDAQ:COCP) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.

Which has more volatility and risk, COCP or ABOS?

Cocrystal Pharma has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Does the media refer more to COCP or ABOS?

In the previous week, Acumen Pharmaceuticals had 6 more articles in the media than Cocrystal Pharma. MarketBeat recorded 9 mentions for Acumen Pharmaceuticals and 3 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.50 beat Acumen Pharmaceuticals' score of 0.29 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Acumen Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor COCP or ABOS?

Acumen Pharmaceuticals received 3 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 77.42% of users gave Cocrystal Pharma an outperform vote while only 72.97% of users gave Acumen Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Cocrystal Pharma	Outperform Votes 24 77.42%	Underperform Votes 7 22.58%
Acumen Pharmaceuticals	Outperform Votes 27 72.97%	Underperform Votes 10 27.03%

Which has higher earnings and valuation, COCP or ABOS?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$17.98M	-$1.57	-0.96
Acumen Pharmaceuticals	N/A	N/A	-$52.37M	-$1.94	-0.55

Do analysts recommend COCP or ABOS?

Cocrystal Pharma currently has a consensus target price of $7.00, suggesting a potential upside of 362.05%. Acumen Pharmaceuticals has a consensus target price of $7.33, suggesting a potential upside of 591.82%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Acumen Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Do institutionals & insiders have more ownership in COCP or ABOS?

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 28.1% of Cocrystal Pharma shares are held by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is COCP or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -32.99% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-94.62%	-78.24%
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%

Summary

Acumen Pharmaceuticals beats Cocrystal Pharma on 10 of the 16 factors compared between the two stocks.